Muscular fitness

American College of Sports Medicine: Position Stand: The recommended quantity and quality of exercise for developing and maintaining cardiorespiratory and muscular fitness, and flexibility in healthy adults

Discriminating between elderly and young using a fractal dimension analysis of centre of pressure

The aim of this project was to evaluate the use of a new analysistechnique, fractal dimension analysis, for quantification of quiet stance centre of pressure (COP). By using a fractal dimension analysis of COP, it might be possible to gain more information about control during quiet stance than traditional analyses have previously allowed. The current project considered a group of young healthy participants and a group of elderly healthy participants to compare traditional measures of COP against a fractal dimension analysis of COP. Results indicated that both types of analyses are able to distinguish between eyes open and eyes closed in the elderly group. However, the fractal dimension analysis more accurately detected differences between the participant groups when standing with their eyes closed. Based on these results it is suggested that fractal dimension analysis is more informative about posture control than traditional measures. It is suggested that a fractal dimension type ofanalysis can be incorporated into clinical testing to identify patients with pathologies

Design of a controlled-release ergometer for the measurement of musculotendinous stiffness of the knee flexors

The stiffness of muscle-tendon units (MTUs) influences many aspects of human movement from athletic performance to injury risk. Presently the controlled-release technique of measuring MTU stiffness has been applied almost exclusively to the distal joints of the body, i.e., the ankle. This is primarily because of the mechanical limitations of implementing this technique. However, in order to better understand how the elastic properties of the MTU affect both performance and injury potential, measurements of MTU stiffness of the more proximal joints must be made. The knee flexors are a logical choice because of the integral role of MTU stiffness of this muscle group in both hamstring strains and knee injury. The purpose of this study was to modify a commercial ergometer so that it could be used to measure the musculotendinous stiffness of the knee flexors. Data are presented for a representative participant to illustrate the feasibility and capability of this ergometer, and the measured MTU stiffness was 519 N[middle dot]m[middle dot]rad-1 at a knee flexion moment of 100 N[middle dot]m. Our results indicate that it is indeed possible to modify a commercial ergometer and measure musculotendinous stiffness of large muscle groups crossing proximal joints

Neuromechanical strategies employed to increase jump height during the initiation of the squat jump

The maximal height attained in a vertical jump is heavily influenced by the execution of a large countermovement prior to the upward motion. When a jump must be executed without a countermovement, as in a squat jump, the maximal jump height is reduced. During such conditions, the human body may use other strategies in order to increase performance. The purpose of this research was to investigate the effects of two strategies employed during the initiation of the squat jump: the premovement silent period (PSP), and the small amplitude countermovement (SACM). Fifteen elite male volleyball players (20:6 1:6 years) and 13 untrained males (20:2 1:7 years) performed 10 maximal effort squat jumps from identical starting positions. The electromyographic activity of the vastus lateralis and biceps femoris was measured in conjunction with the vertical ground reaction force and vertical displacement. It was found that the presence of a PSP or a SACM of 1–3 cm did not increase maximal squat jump height significantly (p > 0:05), in neither the highly trained athletes nor the untrained individuals. These results suggest that these strategies do not play a major role in the determination of jump height. Researchers have assumed that a squat jump is purely concentric, and that there are no facilitating mechanisms present that may influence the performance of the jump. This study provides evidence to support this assumption

The influence of vibration on muscle activation and rate of force development during maximal isometric contractions

ABSTRACT: At present there appears to be a need for research conducted on the effects of vibration on the contractile ability of skeletal muscle tissue. The aim of this study was to address this issue by examining the effects of a superimposed muscle/tendon vibration at 50.42±1.16 Hz (acceleration 13.24 ± 0.18ms-2: displacement ≈5mm) on muscular activation and maximal isometric contraction. Sixteen participants with a mean age, body mass, and height of 22 ± 4.4 years, 73.2 ± 11.7 kg and 173.1 ± 9.7 cms, respectively, were recruited for this study. Electromyography and accelerometry from the rectus femoris, and maximal isometric force data characteristics were collected from the dominant limb under conditions of vibration, and no-vibration. A superimposed 50 Hz vibration was used during the contraction phase for the maximal isometric leg extension for the condition of vibration. A one-way ANOVA revealed no significant (p > 0.05) differences between the vibration and no-vibration conditions for peak normalized EMGRMS (84.74% Vs 88.1%) values. An ANOVA revealed significant (p > 0.05) differences between the peak fundamental frequencies of the FFT between the conditions vibration (27.1 ± 12.2 Hz) and novibration (9.8 ± 3.5 Hz). Peak isometric force, peak rate of force development, rate of force development at times 0.05, 0.01, 0.1, 0.5 seconds, and rate of force development at 50, 75, and 90% of peak force were not significantly different. The results of this study suggest that the application of vibration stimulation at 50 Hz during the contraction does not contribute to muscle activation, or enhance force production for maximal isometric contractions

Determining the optimal load for jump squats : a review of methods and calculations

There has been an increasing volume of research focused on the load that elicits maximum power output during jump squats. Because of a lack of standardization for data collection and analysis protocols, results of much of this research are contradictory. The purpose of this paper is to examine why differing methods of data collection and analysis can lead to conflicting results for maximum power and associated optimal load. Six topics relevant to measurement and reporting of maximum power and optimal load are addressed: (a) data collection equipment, (b) inclusion or exclusion of body weight force in calculations of power, (c) free weight versus Smith machine jump squats, (d) reporting of average versus peak power, (e) reporting of load intensity, and (f) instructions given to athletes/ participants. Based on this information, a standardized protocol for data collection and reporting of jump squat power and optimal load is presented

Further evidence to change the medical classification system of the National Wheelchair Basketball Association

A number of researchers have long questioned systems used for classifying athletes with disabilities. Wheelchair basketball players have gained much attention from researchers. Despite this, no change to the NWBA classification system has been made since it was first adopted in 1984. This study investigated the NWBA classification system. At two summer basketball camps, 46 players were tested to assess player sprint performance and stratification under the NWBA medical classification system. The group consisted of Class 1, 2, and 3 players. Electronic timing gates were used to collect 20 meter sprint-times. Results indicate that Class 1 players were significantly slower compared to Class 2 and 3 players (p < .05) with no difference between Class 2 and 3. The results of this study support a change to this system

Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study

Background: Interstitial lung disease is a known complication of rheumatoid arthritis, with a lifetime risk of developing the disease in any individual of 7·7%. We aimed to assess the safety, tolerability, and efficacy of pirfenidone for the treatment of patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Methods: TRAIL1 was a randomised, double-blind, placebo-controlled, phase 2 trial done in 34 academic centres specialising in interstitial lung disease in four countries (the UK, the USA, Australia, and Canada). Adults aged 18–85 years were eligible for inclusion if they met the 2010 American College of Rheumatology and European Alliance of Associations for Rheumatology criteria for rheumatoid arthritis and had interstitial lung disease on a high-resolution CT scan imaging and, when available, lung biopsy. Exclusion criteria include smoking, clinical history of other known causes of interstitial lung disease, and coexistant clinically significant COPD or asthma. Patients were randomly assigned (1:1) to receive 2403 mg oral pirfenidone (pirfenidone group) or placebo (placebo group) daily. The primary endpoint was the incidence of the composite endpoint of a decline from baseline in percent predicted forced vital capacity (FVC%) of 10% or more or death during the 52-week treatment period assessed in the intention-to-treat population. Key secondary endpoints included change in absolute and FVC% over 52 weeks, the proportion of patients with a decline in FVC% of 10% or more, and the frequency of progression as defined by Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT02808871. Findings: From May 15, 2017, to March 31, 2020, 231 patients were assessed for inclusion, of whom 123 patients were randomly assigned (63 [51%] to the pirfenidone group and 60 [49%] to the placebo group). The trial was stopped early (March 31, 2020) due to slow recruitment and the COVID-19 pandemic. The difference in the proportion of patients who met the composite primary endpoint (decline in FVC% from baseline of 10% or more or death) between the two groups was not significant (seven [11%] of 63 patients in the pirfenidone group vs nine [15%] of 60 patients in the placebo group; OR 0·67 [95% CI 0·22 to 2·03]; p=0·48). Compared with the placebo group, patients in the pirfenidone group had a slower rate of decline in lung function, measured by estimated annual change in absolute FVC (–66 vs –146; p=0·0082) and FVC% (–1·02 vs –3·21; p=0·0028). The groups were similar with regards to the decline in FVC% by 10% or more (five [8%] participants in the pirfenidone group vs seven [12%] in the placebo group; OR 0·52 [95% CI 0·14–1·90]; p=0·32) and the frequency of progression as defined by OMERACT (16 [25%] in the pirfenidone group vs 19 [32%] in the placebo group; OR 0·68 [0·30–1·54]; p=0·35). There was no significant difference in the rate of treatment-emergent serious adverse events between the two groups, and there were no treatment-related deaths. Interpretation: Due to early termination of the study and underpowering, the results should be interpreted with caution. Despite not meeting the composite primary endpoint, pirfenidone slowed the rate of decline of FVC over time in patients with RA-ILD. Safety in patients with RA-ILD was similar to that seen in other pirfenidone trials. Funding: Genentech